Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human dose-escalation study of flotetuzumab in relapsed/refractory AML or higher-risk MDS
MOH_2021-06-20_010060Phase 2Recruiting
- Sponsor
- MacroGenics
- Start
- May 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flotetuzumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by MacroGenics. Started May 2021; status: recruiting.
02
Drugs
flotetuzumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on MOH_2021-06-20_010060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-06-20_010060.